NP49425 Generic and Biosimilar Transition Medicines
The Common Services Agency (more commonly known as NHS National Services Scotland) (NSS)contractFind a Tender ↗Ref ocds-h6vhtk-0581ea32014L0024active
Estimated value
—
goods
Awarded value
—
Suppliers
75
Lots
10
10 awarded
Published
19 Dec 2025
Description
Supply of generic and biosimilar transition medicines to NHS Scotland.
Scope
- Reference
- ocds-h6vhtk-0581ea
- Commercial tool
- Standalone contract
- Contract dates
- 01 Feb 2026 to 30 Sept 2028
The Framework Agreement includes the option to extend for any number of periods, up to a maximum overall period of thirty-five (35) months, upon giving not less than three (3) months written notice, such notice to expire no later than the date the Framework Agreement is due to expire.
- Main category
- goods
- CPV classifications
- 33600000
- Contract locations
- Scotland
Award criteria
Criteria the buyer will use to evaluate bids.
| Name | Description | Type | Weighting |
|---|---|---|---|
| Supply Chain | 5 | quality | — |
| — | 95 | price | — |
Submission & procedure
- Procedure
- Open procedure
Award details· 10 awards
Awarded supplier(s), contract period and value as published in the award notice.
Awarded value
—
Award date
—
Contract start
—
Contract end
—
Awarded to
ML
SS
SA
PF
SA
Lots · 10 total
Divisions of the contract. Each lot can be awarded separately.
| Lot | Title | Est. value | Status |
|---|---|---|---|
| 1 | Cytokine Modulators (Golimumab, Tocilizumab, and Etanercept) | £100.0m | cancelled |
| 2 | Cytokine Modulators (Omalizumab) | £15.6m | cancelled |
| 3 | Gastrointestinal, Endocrine, Blood, and Multiple Sclerosis Medicines | £26.2m | cancelled |
| 4 | Denosumab (Osteoporosis) and Ferric Carboxymaltose | £27.4m | cancelled |
| 5 | Apremilast | £1.5m | cancelled |